Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 7/20 | 0.58 |
| ▸ | CTSL | P07711 | 3/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | CTSK | P43235 | 3/20 | 0.56 |
| ▸ | CTSH | P09668 | 1/20 | 0.56 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.53 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 2/20 | 0.52 |
| ▸ | MC5R | P33032 | 2/20 | 0.52 |
| ▸ | MC3R | P41968 | 2/20 | 0.52 |
| ▸ | MC1R | Q01726 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593371 | 0.95 | CXCR4 (0.60) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31593309 | 0.95 | CXCR4 (0.59) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31593257 | 0.93 | CXCR4 (0.59) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31593303 | 0.93 | CXCR4 (0.59) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31593313 | 0.91 | CXCR4 (0.57) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31593271 | 0.91 | CXCR4 (0.57) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31593246 | 0.91 | CXCR4 (0.55) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31593259 | 0.91 | CXCR4 (0.55) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31593283 | 0.91 | CXCR4 (0.58) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31593273 | 0.90 | CXCR4 (0.54) | CXCR4CTSLCTSSCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | CXCR4 2331/4885CTSL 904/4885CTSS 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.